The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Open accessAbstract
BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. (Funded by the European Union and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Low-density lipoprotein (LDL) cholesterol and triglyceride-rich remnant lipoproteins are causally associated with risk of atherosclerotic vascular disease [3][4][5][6]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [4]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“Some rare heterozygous loss-of-function (LOF) variants are associated with reduced TG levels. These patients show protection from ASCVD providing important evidence for a causal role of TG for ASCVD.”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Such LOF variants of APOC3 are also associated with reduced ASCVD risk.10”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.86,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Pre-mRNA splicing and human diseasePreprint
Faustino, N. A., & Cooper, T. A. (2003) · Genes & Development · doi:10.1101/gad.1048803 · Cited by 1,248
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 701–800 of 923
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Pan, J. B., Wang, X., Zhang, Y., Wang, T., Lv, S., Zhang, X., Zhou, Y., Peng, T., & Song, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70542 · Cited by 4
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.958147 · Cited by 4
Crandell, J. R. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s38123 · Cited by 4
Wijeysundera, H. C., Koh, M., Alter, D. A., Austin, P. C., Jackevicius, C. A., Tu, J. V., & Ko, D. T. (2017) · Open Heart · doi:10.1136/openhrt-2017-000731 · Cited by 4
Bozzetto, L., Berntzen, B. J., Kaprio, J. A., Rissanen, A., Taskinen, M., & Pietiläinen, K. H. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.10.005 · Cited by 4
N-acetylgalactosamine (GalNAc)-conjugates: Delivering oligonucleotide drugs to the liver
Sharma, V., Olety, B., & Prasad, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00016-6 · Cited by 4
Peng, Y., Chen, G., & Zheng, H. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.08.11 · Cited by 4
Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis
Scheja, L., & Heeren, J. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_363 · Cited by 4
Llamas‐Ramos, I., Llamas‐Ramos, R., Alonso‐Domínguez, R., Gómez‐Sánchez, L., Tamayo‐Morales, O., Lugones‐Sánchez, C., Rodríguez‐Sánchez, E., García‐Ortiz, L., & Gómez-Marcos, M. Á. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095450 · Cited by 4
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 4
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2553-7_14 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Koška, J., Hansen, S. L., Hu, Y., Jensen, M., Billheimer, D. D., Nedelkov, D., Budoff, M. J., Allison, M., McClelland, R. L., & Reaven, P. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117584 · Cited by 4
Majithia, A. R., Altshuler, D., & Hirschhorn, J. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00004-6 · Cited by 4
Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico
Lopez-Sendon, J. L., Castro, A., & Dalmau, R. (2017) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30011-1 · Cited by 7
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?
Santos, R. D., & Barter, P. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00845 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
Hallengren, E., Almgren, P., Engström, G., Persson, M., & Melander, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128348 · Cited by 4
Mutation detection in Chinese patients with familial hypercholesterolemia
Du, R., Fan, L., Lin, M., He, Z., Huang, H., Chen, Y., Li, J., Xia, K., Zhao, S., & Xiang, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-3763-3 · Cited by 4
Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
Bhatia, V., Arora, P., Kaur, G., & Kaul, U. (2017) · Heart Research - Open Journal · doi:10.17140/hroj-4-135 · Cited by 3
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
Davidson, J., & Rotondo, D. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000510 · Cited by 4
Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
Natarajan, P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405647 · Cited by 4
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 4
Farstad-O’Halloran, K., Sooda, A., Iqbal, T., Wilton, S. D., & Aung-Htut, M. T. (2025) · Genes · doi:10.3390/genes16040412 · Cited by 3
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Thomas, J., Bamhare, P. M., Mulangala, J., Bursill, C. A., Nicholls, S. J., Bartolo, B. A. D., & Bubb, K. J. (2025) · The FASEB Journal · doi:10.1096/fj.202502155r · Cited by 3
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
Nguyen, T. N., Kim, H.-J., Shim, H. M., Kang, J., Ha, E. Y., Cho, H., & Park, J. (2026) · Biomolecules · doi:10.3390/biom16040607 · Cited by 3
Li, W., Wang, Y., Huang, R., Feng, L., Xu, G.-X., Wang, W., & Xue, S. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03759-5 · Cited by 3
The Significance of Lipoproteins in the Development of Obesity
Blagov, A. V., Rufanov, K. A., Irina, K., Sukhorukov, V. N., Goncharov, A., Pleshko, E. M., & Orekhov, A. N. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601008 · Cited by 3
Gomes, L. L. A., Faden, D. F., Xie, L., Chambers, S., Stone, C. J., Werth, V. P., & Williams, K. J. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001160 · Cited by 3
Nutrigenomics: Tailoring Nutrition Based on Genes
Wheatley, M. C. (2024) · Premier Journal of Genetics · doi:10.70389/pjg.100002 · Cited by 4
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Han, Y., Qi, R., & Liu, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.147 · Cited by 3
Next-generation gene discovery for variants of large impact on lipid traits
Rosenthal, E. A., Blue, E., & Jarvik, G. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000156 · Cited by 3
Human genes lost and their functions found
Plenge, R. M. (2017) · Nature · doi:10.1038/544171a · Cited by 3
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Yang, S., & Moon, Y.-A. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0353-5 · Cited by 3
Kumar, A., Patel, D. R., Brennan, D. M., Wolski, K., Lincoff, A. M., Ruotolo, G., McErlean, E. S., Weerakkody, G. J., Riesmeyer, J. S., Nicholls, S. J., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013790 · Cited by 3
The forkhead box O family in insulin action and lipid metabolism
Lee, S., Zhu, C., Yamauchi, J., Zhu, P., Feng, X., Qu, S., & Dong, H. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00013-0 · Cited by 3
Shou, W., Zhang, C., Shi, J., Wu, H., & Huang, W. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.11.010 · Cited by 3
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
Alternative Natural Management of Dyslipidemia
Al-Kushi, A. G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82430 · Cited by 4
Blauw, L. L., Noordam, R., van der Laan, S. W., Trompet, S., Kooijman, S., van Heemst, D., Jukema, J. W., van Setten, J., de Borst, G. J., Tybjærg‐Hansen, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050932 · Cited by 3
Self-citationLüscher, T. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv049 · Cited by 3
Where to now in cardiovascular disease prevention
Najam, O., & Ray, K. K. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.036 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 3
Self-citationDarabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 3
Polygenic Hyperlipidemias and Coronary Artery Disease RiskPreprint
Ripatti, P., Rämö, J. T., Mars, N., Söderlund, S., Benner, C., Surakka, I. L., Kiiskinen, T., Havulinna, A. S., Palta, P., Freimer, N. B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/735167 · Cited by 3
APOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
Hipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 2
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 2
Liu, Y., Skudder‐Hill, L., Ko, J., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Nutrients · doi:10.3390/nu17233718 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Zhou, Z., Chen, J., Wang, H., Han, Y., Liu, C., Shen, Q., Dong, Z., Lu, K., Zhai, C., Xu, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104088 · Cited by 3
Emara, A., Mansour, A., Aboeldahab, H. A., Awashra, A., Abbas, O. F., Abdul‐Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Saif, H. S., Shubietah, A. R. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70716 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
FNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
HDL, heart disease, and the lung
Frey, K., & von Eckardstein, A. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100217 · Cited by 2
Shah, M. A., Sharma, A., Ayyad, M., Swartz, E., Jafrani, D., & Gala, D. (2024) · Cureus · doi:10.7759/cureus.67091 · Cited by 2
Mottelson, M., Helby, J., Petersen, J., Nordestgaard, B. G., Bojesen, S. E., Bendtsen, S. K., Rossing, M., Rasmussen, A. Ø., & Glenthøj, A. B. (2024) · American Journal of Hematology · doi:10.1002/ajh.27508 · Cited by 2
Self-citationMolecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 4
Anagnostis, P. G., Rizos, C. V., Liamis, G. L., Rallidis, L. S., Skoumas, I., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., Garoufi, A., Kotsis, V., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.017 · Cited by 2
Lipoproteins and Cardiovascular Disease Risk
Dhingra, R., & Vasan, R. S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_4 · Cited by 2
Nedelkov, D., & Hu, Y.-M. (2019) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2019-0977 · Cited by 3
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e20 · Cited by 2
Self-citationGenetic Influences on Blood Lipids and Cardiovascular Disease Risk
Pollin, T. I., Ordovás, J. M., & Guevara‐Cruz, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00026-6 · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
A Novel Biomarker Approach to Exploit HDL for Risk Assessment
von Eckardstein, A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.040 · Cited by 2
Human apolipoprotein CIII levels; evaluation of three assay methods
Sandin, Å., Olofsson, C., Strålfors, A., Ekberg, N. R., Brismar, K., Juntti‐Berggren, L., & Eggertsen, G. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1725976 · Cited by 2
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Prédire les crises bancaires : un système d’alerte robuste
Jedidi, O., & Pentecôte, J.-S. (2016) · Revue française d économie · doi:10.3917/rfe.153.0189 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 2
Endogenous and exogenous factors affecting lipoprotein lipase activity
Larsson, M. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Slippery Slope of Triglycerides
Watson, K. E., & Wiesner, P. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002675 · Cited by 2
What are the prospects of apolipoprotein profiling for cardiovascular disease?
Baig, F., & Mayr, M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1352472 · Cited by 2
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity
Arndt, L., & Burkhardt, R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000501 · Cited by 2
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Self-citationMalick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 1
Hypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 1
ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction
Holzer, M., Gruden, E., Ćurčić, S., Cvirn, G., & Marsche, G. (2025) · Cells · doi:10.3390/cells14181411 · Cited by 1
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Rasmussen, K. L., Luo, J., Nielsen, S. P., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.70124 · Cited by 1
Self-citationMeghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
Dyslipidemias in Chronic Kidney Disease: Pathophysiology and Emerging Therapies
Capón, I. M., Lerma, E. V., Anandh, U., So, P. N., & Hassanein, M. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_711_2025 · Cited by 1
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 2
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 2
Li, Q., Si, J., Jin, Q., Li, S., Guo, Y., Han, P., & Zhang, F. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101824 · Cited by 1
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Perspektiven zu cholesterinwirksamer Behandlung 2014
Klose, G., Schulz, R., & Köenig, W. (2014) · CardioVasc · doi:10.1007/s15027-014-0521-8 · Cited by 1
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 32-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052644460
- Semantic Scholar
- 55f5e169d6f4d9a568cca4bbafe0790022e8bc16
- Cited by
- 919
- References
- 39
- Citations by year
- 2026: 50 · 2025: 76 · 2024: 49 · 2023: 46 · 2022: 65 · 2021: 64 · 2020: 95 · 2019: 71 · 2018: 71 · 2017: 99 · 2016: 113 · 2015: 87 · 2014: 32
- FWCI
- 75.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, ischemic vascular disease, ischemic heart disease, cardiovascular risk, heterozygosity, genetic variants, triglyceride lowering, general population, hypertriglyceridemia, genetic epidemiology, Mendelian randomization
- MeSH terms
- Adult, Aged, Female, Genotype, Humans, Ischemia, Cholesterol, LDL, Liver, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Incidence, Myocardial Ischemia, Sequence Analysis, DNA, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
